Pharmaceutical companies are leveraging AI to optimize sales and marketing operations, with Scotiabank projecting $770B in incremental revenue and $50B in cost savings by 2028. The focus shifts from drug discovery to commercial execution.
AI Adoption in Pharma Prioritizes Commercial Operations Over Discovery
Artificial intelligence is reshaping the pharmaceutical industry, but not in the way many investors anticipated. While AI's potential in drug discovery remains a long-term aspiration, the immediate financial impact is emerging from commercial applications, according to a Scotiabank analysis. Companies are deploying AI tools to enhance sales-force productivity, accelerate compliant content creation, and streamline market access strategies.
The report highlights that AI-driven commercial improvements could generate roughly 3% revenue accretion by 2028 across large-cap biopharma firms, with cost savings materializing as infrastructure investments mature. This translates to an estimated $770 billion in cumulative incremental revenue and $50 billion in savings over the next decade. The shift underscores how AI is addressing data-heavy, repetitive workflows in sales, marketing, and regulatory processes.
Key Applications and Market Leaders
Industry leaders are already integrating AI into their commercial frameworks. Pfizer's Charlie platform aims to speed up marketing content creation by 3-5x, while Merck has reduced marketing material production timelines by up to 80%. Johnson & Johnson uses AI to prepare sales reps for provider interactions, and Gilead employs next-best-action models for field teams. AbbVie and Teva have similarly adopted AI for sales planning and pharmacy account optimization.
These tools improve targeting accuracy, reduce compliance bottlenecks, and enhance campaign performance. For instance, next-best-action tools have reportedly boosted "impactable sales" by 5% for certain products, a significant figure in an industry where blockbuster drugs generate billions annually.
Implications for Investors and Traders
Investors may be overvaluing AI's role in drug discovery, which faces scientific and logistical hurdles. Commercial AI, by contrast, offers measurable, short-term returns. The focus on operational efficiency could drive operating leverage, reducing reliance on external agencies and incremental hiring. This trend may favor established pharma companies with robust commercial infrastructures over startups with unproven discovery models.
For Forex traders, the broader implications tie to risk sentiment. Improved pharma sector performance could signal resilience in healthcare equities, influencing equity-linked currencies and risk-on/risk-off dynamics. However, the direct FX impact remains limited unless tied to central bank policies or macroeconomic shifts.
Risks and Outlook
While AI's commercial benefits are tangible, challenges persist. Medical-legal review processes, though streamlined, remain critical for compliance. Additionally, the long-term potential of AI in drug discovery cannot be ignored, though it may take years to materialize. Traders should monitor pharma earnings reports and AI adoption metrics for signals of sustained margin expansion.
Risk Disclaimer: This analysis is for informational purposes only. Trading involves risks, and past performance does not guarantee future results. Consult a financial advisor before making investment decisions.
Risk warning
Trading Forex and CFDs carries a high level of risk and may not be suitable for all investors. You may lose more than your initial investment. Past performance is not indicative of future results. This site is informational and does not constitute investment advice.